Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects With Recurrent/Refractory Brain Tumors and Newly Diagnosed Brain Stem Glioma
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 20 Nov 2019
Price : $35 *
At a glance
- Drugs APX 005M (Primary)
- Indications CNS cancer; Glioma
- Focus Adverse reactions; Pharmacokinetics
- 18 Nov 2019 Status changed from recruiting to active, no longer recruiting.
- 18 Mar 2019 Planned primary completion date changed from 30 Sep 2019 to 30 Sep 2020.
- 02 Feb 2018 Status changed from not yet recruiting to recruiting.